Welcome to our dedicated news page for Champions Oncology (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncology.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Champions Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Champions Oncology's position in the market.
Rhea-AI Summary
Champions Oncology, Inc. (NASDAQ:CSBR) reports third quarter financial results with a revenue decline of 6% to $12.0 million. The company aims to navigate through economic challenges in the biotech sector and is actively engaging with investors to raise capital for its subsidiary, Corellia, AI. Despite lower revenue growth, Champions is strategically reducing costs to improve short-term results. The company's loss from operations for the third quarter of fiscal 2024 was $2.6 million, with an adjusted EBITDA loss of $1.7 million. Total revenue for the first nine months of fiscal 2024 decreased by 11.4% to $36.2 million compared to the same period last year. Champions ended the quarter with approximately $4.5 million in cash and cash equivalents, with no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
-
Rhea-AI Summary
Champions Oncology (CSBR) receives CAP accreditation for its US-based laboratory, further solidifying its reputation for excellence in histology and immunohistochemistry services. The company also attains ISO-9001:2015 and ATS certifications at its European Research Laboratories in Italy, showcasing its commitment to quality. CEO Ronnie Morris emphasizes the importance of these achievements in maintaining high scientific standards and contributing to partners' therapeutic studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
-
Rhea-AI Summary
Champions Oncology, Inc. (CSBR) will release its Q3 financial and operational results on March 12, 2024, followed by a conference call. The call will discuss the company's performance and future outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
Rhea-AI Summary
Champions Oncology, Inc. (NASDAQ:CSBR) announced its second quarter fiscal 2024 financial results, reporting a 19% decline in revenue, revised revenue guidance, and key strategic initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.42%
Tags
-
Rhea-AI Summary
Champions Oncology, Inc. (CSBR) will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company offers end-to-end oncology solutions and will host a conference call to discuss the results at 4:30 P.M. EST (1:30 P.M. PST).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
-
Rhea-AI Summary
Champions Oncology, a global preclinical and clinical research services provider, announced that its European research operations site in Bresso, Italy, received ISO-9001:2015 laboratory accreditation and ATS certification. These achievements validate the quality of clinical testing services and enable specialty testing of clinical patient samples for global biopharma partners in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
Rhea-AI Summary
Champions Oncology appoints Brady Davis as President to drive accelerated growth
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Summary
Champions Oncology announces Q1 2024 financial results with revenue of $12.6 million, a decline of 9%. Quarterly bookings are strong. CEO expects positive trend in customer spending and reduction in cancellations. CFO anticipates increasing revenue and improving financial performance throughout the year. Net loss from operations was $2.6 million. Gross margin decreases to 38.8% from 48.7% due to lower revenue conversion percentages and increase in outsourced services. Company ends quarter with $5.0 million in cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
-
News
Rhea-AI Summary
Champions Oncology to report Q1 financial results on September 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
Rhea-AI Summary
Champions Oncology kicks off its annual series of events by hosting a scientific symposium in Boston on September 26th. The event will focus on integrative approaches for oncology drug development and feature speakers from biopharma companies. The symposium is sponsored by Champions in partnership with BGI Americas and Emulate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
Champions Oncology, Inc.
Nasdaq:CSBR
CSBR Rankings
CSBR Stock Data
66.07M
4.72M
25.56%
42.15%
0.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
BALTIMORE
About CSBR
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them